Plasmacytoid dendritic cells in the setting of myeloid neoplasms: Diagnostic guide to challenging pathologic presentations

Br J Haematol. 2023 Mar;200(5):545-555. doi: 10.1111/bjh.18632. Epub 2023 Jan 6.

Abstract

In this article, we describe three broad pathologic presentations of plasmacytoid dendritic cells (pDCs) that may be encountered in clinical practice, in which an association between pDCs and myeloid neoplasms is identified: (1) myeloid neoplasms with mature pDC expansion, most commonly seen in chronic myelomonocytic leukaemia (CMML); (2) myeloid neoplasms with pDC differentiation, in which pDCs show a spectrum of maturation from early immature pDCs to mature forms, most commonly seen in acute myeloid leukaemia (AML); (3) myeloid neoplasms associated with blastic plasmacytoid dendritic cell neoplasm (BPDCN), either stemming from the same precursor or representing an independent clonal process. Additionally, we also discuss AML with pDC-like phenotype, in which myeloblasts show immunophenotypic features that may mimic those seen in pDCs. Using these presentations, we provide a diagnostic algorithm for appropriate pathologic classification, while attempting to clarify and homogenize nomenclatures pertaining to different biologic states of pDCs.

Keywords: differentiation; expansion; myeloid neoplasms; pDCs; plasmacytoid dendritic cells.

Publication types

  • Review

MeSH terms

  • Cell Differentiation
  • Dendritic Cells / pathology
  • Humans
  • Leukemia, Myelomonocytic, Chronic* / diagnosis
  • Leukemia, Myelomonocytic, Chronic* / pathology
  • Myeloproliferative Disorders* / diagnosis
  • Myeloproliferative Disorders* / pathology
  • Phenotype